Mammoth Biosciences
Brisbane, US · Founded 2017 · Delaware corporation · 16 known investors
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
Founders & leadership
Investors · 16
8VCAustin · $500K – $50M
Berkeley FrontierBerkeley
CALIFORNIA INNOVATIONBerkeley
Decheng CapitalMenlo Park
Foresite CapitalLarkspur
Mayfield FundCupertino · $500K – $12M
Mission Bay CapitalSan Francisco
Mission BiocapitalSan Francisco · $500K
Plum Alley InvestmentsNew York · $500K – $1.5M
Solari CapitalNew York
SV AngelSan Francisco
Tachyon VenturesLos Angeles
Wireframe VenturesSan Francisco · $500K – $2M
Boom Capital VenturesreportedSan Francisco · $50K – $300Kvia Celestine Schnugg · inferred
K50 VenturesreportedEncinitas · $50K – $250K
NFXreportedSan Francisco · $250K – $5M
Reported raises · per SEC filings
Form D private placements▶$13.2MraisedAug 2018 · 28 investors · BiotechnologyRule 506(b)
▶$13.2MraisedAug 2018 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Urshit ParikhDirector
- Ashley TehranchiExecutive Officer, Director
- Janice ChenExecutive Officer
- Trevor MartinExecutive Officer, Director
- Lucas HarringtonExecutive Officer
- Offering amount
- $13.2M
- Amount sold
- $13.2M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$7.4MraisedAug 2018 · 4 investors · BiotechnologyRule 506(b)
▶$7.4MraisedAug 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lucas HarringtonExecutive Officer
- Urshit ParikhDirector
- Trevor MartinExecutive Officer, Director
- Ashley TehranchiExecutive Officer, Director
- Janice ChenExecutive Officer
- Offering amount
- $7.4M
- Amount sold
- $7.4M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Sell or Invest in Mammoth Biosciences Stock Pre-IPOnasdaqprivatemarket.com · 2024
- Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnosticsbusinesswire.com · 2021
- Mammoth Biosciences Achieves Unicorn Status with $195M Fundingmayfield.com · 2021
- Star-Studded Mammoth Bio Raises $45 Million for Crispr R&D - Bloombergbloomberg.com · 2020
- Mammoth Biosciences Raises $45M in Series B Funding Round - FinSMEsfinsmes.com · 2020
- Mammoth Bio raises $23 mln to fund CRISPR-based technology | Reutersreuters.com · 2018
